Can weight loss pills affect your period? For many women, this is an important question before starting any weight management medication. The short answer is yes — though usually indirectly. Licensed weight loss medicines such as orlistat, semaglutide (Wegovy), and naltrexone/bupropion (Mysimba) do not typically alter the menstrual cycle through direct hormonal action. Instead, changes to your period are more often a consequence of significant or rapid weight loss itself, which can disrupt the hormonal signals that regulate your cycle. Understanding why this happens — and when to seek advice — is essential for protecting your reproductive health.

How Weight Loss Pills Can Affect Your Menstrual Cycle

Weight loss pills do not directly alter the menstrual cycle pharmacologically; menstrual changes are typically a secondary effect of significant weight loss reducing oestrogen levels and disrupting HPO axis signalling.

Weight loss pills can, in some cases, influence your menstrual cycle, though the nature and extent of any effect depends largely on the type of medication involved, the degree of weight loss achieved, and your individual hormonal baseline. For most licensed weight loss medicines, menstrual changes are not a direct pharmacological effect of the drug itself, but rather a secondary consequence of significant or rapid weight loss and the associated changes in energy availability and body composition.

Some women report lighter periods, missed periods (amenorrhoea), or irregular cycles during a period of significant weight loss. These changes typically reflect the body's hormonal response to a meaningful reduction in caloric intake or fat mass. Fat tissue plays an active role in oestrogen production, so a rapid reduction in body fat can lower circulating oestrogen levels, disrupting the hormonal signals that regulate the menstrual cycle.

It is also worth noting that if you use hormonal contraception (such as the combined pill, progestogen-only pill, or hormonal coil), this can independently alter or suppress your bleeding pattern, which may make it difficult to distinguish any effect of weight loss medication from the effect of contraception itself.

All anti-obesity medicines — including GLP-1 receptor agonists, orlistat, and naltrexone/bupropion — are not recommended during pregnancy. If there is any possibility you could be pregnant, or if you are planning a pregnancy, you should discuss this with your GP or prescribing clinician before starting or continuing treatment. If you become pregnant whilst taking any weight loss medication, stop the medicine and seek medical advice promptly.

If you notice changes to your period after starting any weight loss medication, it is worth discussing this with your GP or prescribing clinician, as it may indicate a need to review your treatment plan.

Types of Weight Loss Medication Available in the UK

MHRA-regulated options include orlistat, GLP-1 receptor agonists (semaglutide, liraglutide), and naltrexone/bupropion (Mysimba); unlicensed online products can be dangerous and should be avoided.

In the UK, weight loss medications are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and are typically only prescribed when lifestyle interventions alone have been insufficient. The main options currently available include:

• Orlistat (Alli, Xenical): A lipase inhibitor that reduces dietary fat absorption in the gut. It is available both on prescription and over the counter in a lower-dose form. Orlistat does not act hormonally, but by reducing fat absorption, it may impair the absorption of fat-soluble vitamins (A, D, E, and K), which play supporting roles in reproductive and general health. Based on SmPC guidance, if you are taking orlistat, it is advisable to take a multivitamin containing fat-soluble vitamins at bedtime, separated from your orlistat dose by at least two hours, to help offset this risk.

• GLP-1 receptor agonists (e.g., semaglutide/Wegovy, liraglutide/Saxenda): These injectable medications mimic the glucagon-like peptide-1 hormone, suppressing appetite and slowing gastric emptying. In the NHS, access to these medicines is subject to specific eligibility criteria set out in NICE technology appraisals (e.g., NICE TA875 for semaglutide), and availability may be limited depending on local service capacity. Significant weight loss achieved with these agents may indirectly affect menstrual regularity, but the medicines themselves do not have an established direct effect on the menstrual cycle per their UK SmPCs.

• Naltrexone/bupropion (Mysimba): This combination acts on the central nervous system to reduce appetite and cravings. There is no established direct effect of naltrexone/bupropion on the menstrual cycle or the hypothalamic-pituitary-ovarian (HPO) axis based on the UK SmPC; any menstrual changes are more likely to be secondary to weight loss itself.

It is worth noting that many so-called 'weight loss pills' sold online or in health shops are not licensed medicines and may contain unlisted or harmful ingredients. Some unlicensed products — such as those containing dinitrophenol (DNP) — have caused serious harm and death. The MHRA regularly issues safety warnings about such products. Always source weight loss treatments through a regulated healthcare provider or registered pharmacy, and check the MHRA's guidance on buying medicines safely online.

Why Hormonal and Metabolic Changes Disrupt Periods

Rapid weight loss can suppress GnRH secretion from the hypothalamus, reducing LH and FSH and potentially halting ovulation; conversely, weight loss in PCOS can restore menstrual regularity.

The menstrual cycle is governed by a finely tuned hormonal cascade involving the hypothalamus, pituitary gland, and ovaries — collectively known as the HPO axis. This system is highly sensitive to changes in energy availability, body composition, and metabolic status. When weight loss is rapid or substantial, the body may interpret this as a state of physiological stress or energy deficit, prompting it to suppress reproductive function as a protective mechanism.

A key concept here is functional hypothalamic amenorrhoea (FHA), a condition in which the hypothalamus reduces its secretion of gonadotrophin-releasing hormone (GnRH), leading to lower levels of luteinising hormone (LH) and follicle-stimulating hormone (FSH). Without adequate LH and FSH signalling, ovulation may not occur, and periods can become irregular or stop altogether. This is more commonly associated with extreme caloric restriction or excessive exercise, but significant medically-assisted weight loss can trigger a similar response in susceptible individuals. NICE CKS guidance on amenorrhoea provides further detail on assessment and management.

Additionally, adipose (fat) tissue is a source of peripheral oestrogen synthesis via the conversion of androgens by the enzyme aromatase. A meaningful reduction in fat mass can therefore lower oestrogen levels, thinning the uterine lining and reducing menstrual flow — or preventing menstruation entirely.

Conversely, in women with polycystic ovary syndrome (PCOS), weight loss can actually improve menstrual regularity by reducing insulin resistance and androgen excess. Weight management is a first-line recommendation in NICE CKS guidance on PCOS and in RCOG resources for this condition. The effect of weight loss on periods is therefore not universally negative and is highly context-dependent.

When to Seek Medical Advice About Menstrual Changes

Consult your GP if periods stop for three or more months, bleeding becomes unusually heavy, or you experience intermenstrual spotting; always exclude pregnancy if conception is possible.

Whilst some degree of menstrual change during a period of significant weight loss may be expected, certain symptoms warrant prompt medical attention. You should contact your GP if you experience any of the following:

• Periods that stop entirely for three months or more if your cycles were previously regular, or for six months or more if your cycles were previously irregular (secondary amenorrhoea)

• Unusually heavy or prolonged bleeding — for example, bleeding that lasts more than seven days, passing clots larger than a 10p coin, flooding through protection every one to two hours, or needing to use double protection (in line with NHS and NICE NG88 guidance on heavy menstrual bleeding)

• Severe pelvic pain associated with your cycle

• Spotting or bleeding between periods or after sexual intercourse

• Signs of nutritional deficiency, such as hair loss, fatigue, or brittle nails, which may suggest malabsorption (particularly relevant with orlistat use)

It is also important to consider that missed periods are not always caused by weight loss or medication — pregnancy should be excluded if there is any possibility of conception. A simple urine pregnancy test can be done at home or at your GP surgery. As noted above, all licensed anti-obesity medicines are contraindicated in pregnancy; if you are planning a pregnancy, discuss stopping treatment with your prescriber in advance. For semaglutide (Wegovy), the SmPC advises stopping treatment at least two months before a planned conception.

Regarding contraception: based on UK SmPCs, semaglutide and liraglutide do not have a clinically relevant effect on the absorption of combined oral contraceptives, so standard oral contraception remains effective with these medicines. However, if you are taking other weight loss agents, or if you have any concerns about contraceptive efficacy, discuss this with your prescriber.

Your GP or a specialist in reproductive medicine can carry out investigations including blood tests for hormone levels (LH, FSH, oestradiol, prolactin, thyroid function, and androgens such as total testosterone and SHBG if PCOS is suspected) and a pelvic ultrasound if clinically indicated. Note that interpretation of hormone results may be affected by hormonal contraception use.

If you think your menstrual changes may be a side effect of a weight loss medicine, you can report this via the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk). This helps the MHRA monitor the safety of medicines in the UK.

Experiencing these side effects? Our pharmacists can help you navigate them →

Safer Approaches to Weight Management and Hormonal Health

A gradual loss of 0.5–1 kg per week, adequate micronutrient intake, and regular clinical review minimise hormonal disruption; women with PCOS should use effective contraception as fertility may improve with weight loss.

For most women, a gradual and sustainable approach to weight management is less likely to disrupt menstrual function than rapid or extreme weight loss. NICE NG246 (Obesity: identification, assessment and management) recommends a structured programme combining dietary changes, increased physical activity, and behavioural support as the foundation of weight management, with pharmacological treatment considered as an adjunct rather than a standalone solution.

If you are considering or currently using weight loss medication, the following steps can help protect your hormonal health:

• Ensure adequate nutritional intake: Even when in a caloric deficit, aim to meet your requirements for key micronutrients, particularly iron, vitamin D, calcium, and B vitamins, which support both metabolic and reproductive health. If you are taking orlistat, take a multivitamin containing fat-soluble vitamins (A, D, E, and K) at bedtime, at least two hours after your last orlistat dose.

• Avoid overly rapid weight loss: A rate of 0.5–1 kg per week is generally considered safe and is less likely to trigger hormonal disruption than faster approaches.

• Be aware that weight loss can improve fertility: Particularly in women with PCOS, losing weight may restore ovulation and increase the chance of conception. If you are not planning a pregnancy, ensure you are using effective contraception.

• Plan ahead if you are considering pregnancy: Discuss stopping anti-obesity medication with your prescriber before trying to conceive. For semaglutide, the SmPC advises a washout period of approximately two months before planned conception.

• Monitor your cycle: Keeping a record of your periods using a diary or app can help you and your clinician identify patterns and changes over time.

• Discuss your full medical history with your prescriber: Conditions such as PCOS, thyroid disorders, or a history of disordered eating can all influence how your body responds to weight loss interventions.

Weight loss medication should always be used under appropriate medical supervision, with regular follow-up to monitor both effectiveness and any emerging side effects. If menstrual changes are causing concern, a joined-up conversation between your GP and any specialist involved in your weight management care is the most effective way to ensure your overall health — including your reproductive health — is properly supported. Suspected side effects from any weight loss medicine can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions